To finalise this methodology, the Benchmark research team conducted a targeted review of the previous methodological framework, which included checks of indicators, data sets and analytical approaches, and consultations with expert stakeholders to reconfirm the appropriate role for pharmaceutical companies on AMR. A committee of independent experts (including academics, investors, public sector and industry representatives) reviewed the methodology.
What the Benchmark measures:
Includes large research-based pharmaceutical companies, generic medicine manufacturers; and small and medium-sized enterprises (SMEs, not scored, will be evaluated in standalone report)
Bacteria and fungi, including those defined as priority bacteria and fungi by the CDC and WHO
Includes antimicrobial medicines and vaccines that target bacterial and fungal infections in humans.
Medicines: all innovative, adaptive and (branded) generic medicine; and
Vaccines: both preventive and therapeutic vaccines that target bacteria or fungi
Includes 102 'access countries' in which challenges around availability of products, and appropriate access, remain significantly higher.